Collplant Biotechnologies is a biotechnology business based in the US. Collplant Biotechnologies shares (CLGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.23 – a decrease of 0.47% over the previous week. Collplant Biotechnologies employs 75 staff and has a trailing 12-month revenue of around $689,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $4.23 |
|---|---|
| 52-week range | $3.61 - $6.99 |
| 50-day moving average | $4.47 |
| 200-day moving average | $5.08 |
| Wall St. target price | $12.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.53 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.15 from 2024-11-18
| 1 week (2024-11-13) | -3.71% |
|---|---|
| 1 month (2024-10-18) | -0.81% |
| 3 months (2024-08-20) | -14.43% |
| 6 months (2024-05-20) | -32.96% |
| 1 year (2023-11-20) | -25.63% |
|---|---|
| 2 years (2022-11-18) | -23.85% |
| 3 years (2021-11-19) | 18.94 |
| 5 years (2019-11-20) | 4.95 |
| Revenue TTM | $689,000 |
|---|---|
| Gross profit TTM | $13.6 million |
| Return on assets TTM | -33.77% |
| Return on equity TTM | -61.55% |
| Profit margin | 0% |
| Book value | $1.81 |
| Market Capitalization | $48.7 million |
TTM: trailing 12 months
We're not expecting Collplant Biotechnologies to pay a dividend over the next 12 months.
Collplant Biotechnologies's shares were split on a 2:3 basis on 20 November 2016 . So if you had owned 3 shares the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Collplant Biotechnologies shares – just the quantity. However, indirectly, the new 50% higher share price could have impacted the market appetite for Collplant Biotechnologies shares which in turn could have impacted Collplant Biotechnologies's share price.
Over the last 12 months, Collplant Biotechnologies's shares have ranged in value from as little as $3.61 up to $6.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Collplant Biotechnologies's is 0.483. This would suggest that Collplant Biotechnologies's shares are less volatile than average (for this exchange).
CollPlant Biotechnologies Ltd. , a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.